Swiss Product Management 2013/14 : Von den Besten lernen

StudieIm Rahmen der Studie wurden 389 Entscheidungsträger zu ihrem Rollenverständnis, ihren Herausforderungen und den relevanten Trends im Product Management befragt. Das diesjährige Motto der Studie lautet "Von den Besten lernen" – es stellt sich die Frage: Was machen erfolgreiche Product Manager besser als ihre weniger erfolgreichen Kollegen

Swiss CRM 2013 : Einsatz und Trends in Schweizer Unternehmen

StudieDie aktuelle Swiss CRM Studie beleuchtet den Status Quo sowie die Trends des CRM in der Schweiz. Der Schwerpunkt der diesjährigen Ausgabe liegt im Bereich Customer Experience Management. Dabei wird erstmals nicht nur die Unternehmenssicht, sondern auch die Kundenperspektive am Beispiel von drei teilnehmenden Unternehmen abgefragt

Der Schlüssel zu einem erfolgreichen Product Management

Was machen erfolgreiche Unternehmen bezüglich ihres Product Managements anders und inwiefern können andere von ihnen lernen? Diese zwei Fragen standen im Mittelpunkt der Studie «Swiss Product Management 2013/2014 – Von den Besten lernen»

Welche CRM-Trends Schweizer Unternehmen beschäftigen

Die Schweizer Unternehmen sehen sich im harten Kampf um die Kunden. Wo die Qualität der Leistungen keine ausreichende Differnzierung mehr ermöglicht, setzten sie auf Erlebnis- und Beziehungsqualität. Personalisierung und Mobile CRM sind dabei die steigenden Trends des Jahres

Scenari di ricostruzione delle interazioni uomo-ambiente-clima in Lombardia (N-Italia) dal Paleolitico medio all’età del Ferro

This contribution aims to provide an updated and concise overview of the main events and developments characterising the interaction between human communities and their environment in Lombardy (Northern Italy) between the Middle Paleolithic and the Late Iron Age (60,000 to 2,100 years cal BP). Within the above defined geographic and chronological context, our main goal is to highlight and summarise the role of natural factors in the development of human history, both over the long durée and within defined periods. We provide a short history of the ecosystems and socio-ecological systems in Lombardy, for which – thanks to the contribution of several research groups and scholars active in the region – we analyse specific key issues. These analyses are facilitated by chronostratigraphic tables and GIS-based cartography, and introduced by an overview of the climatic changes that affected Alpine and Po Plain landscapes across the Last Glaciation and subsequent Late Glacial times, up to the shortlasting events which influenced the development of Holocene civilisations. The structure and significance of the issues introduced in the overview will be discussed by individual research groups working within this study are

Characterising key issues in human–environment interactions in Lombardy (N-Italy) from the Middle Paleolithic to the Iron Age

This contribution aims to provide an updated and concise overview of the main events and developments characterising the interaction between human communities and their environment in Lombardy (Northern Italy) between the Middle Paleolithic and the Late Iron Age (60,000 to 2,100 years cal BP). Within the above defined geographic and chronological context, our main goal is to highlight and summarise the role of natural factors in the development of human history, both over the long durée and within defined periods. We provide a short history of the ecosystems and socio-ecological systems in Lombardy, for which – thanks to the contribution of several research groups and scholars active in the region – we analyse specific key issues. These analyses are facilitated by chronostratigraphic tables and GIS-based cartography, and introduced by an overview of the climatic changes that affected Alpine and Po Plain landscapes across the Last Glaciation and subsequent Late Glacial times, up to the shortlasting events which influenced the development of Holocene civilisations. The structure and significance of the issues introduced in the overview will be discussed by individual research groups working within this study are

Tocilizumab for treatment of severe covid-19 patients: Preliminary results from smatteo covid19 registry (smacore)

Objective: This study aimed to assess the role of Tocilizumab therapy (TCZ) in terms of ICU admission and mortality rate of critically ill patients with severe COVID-19 pneumonia. Design: Patients with COVID-19 pneumonia were prospectively enrolled in SMAtteo COvid19 REgistry (SMACORE). A retrospective analysis of patients treated with TCZ matched using propensity score to patients treated with Standard Of Care (SOC) was conducted. Setting: The study was conducted at IRCCS Policlinico San Matteo Hospital, Pavia, Italy, from March 14, 2020 to March 27, 2020. Participants: Patients with a confirmed diagnosis of COVID-19 hospitalized in our institution at the time of TCZ availability. Interventions: TCZ was administered to 21 patients. The first administration was 8 mg/kg (up to a maximum 800 mg per dose) of Tocilizumab intravenously, repeated after 12 h if no side effects were reported after the first dose. Main Outcomes and Measures: ICU admission and 7-day mortality rate. Secondary outcomes included clinical and laboratory data. Results: There were 112 patients evaluated (82 were male and 30 were female, with a median age of 63.55 years). Using propensity scores, the 21 patients who received TCZ were matched to 21 patients who received SOC (a combination of hydroxychloroquine, azithromycin and prophylactic dose of low weight heparin). No adverse event was detected following TCZ administration. This study found that treatment with TCZ did not significantly affect ICU admission (OR 0.11; 95% CI between 0.00 and 3.38; p = 0.22) or 7-day mortality rate (OR 0.78; 95% CI between 0.06 and 9.34; p = 0.84) when compared with SOC. Analysis of laboratory measures showed significant interactions between time and treatment regarding C-Reactive Protein (CRP), alanine aminotransferase (ALT), platelets and international normalized ratio (INR) levels. Variation in lymphocytes count was observed over time, irrespective of treatment. Conclusions: TCZ administration did not reduce ICU admission or mortality rate in a cohort of 21 patients. Additional data are needed to understand the effect(s) of TCZ in treating patients diagnosed with COVID-19